Bitten by the Bug – A flurry of investments fuel microbiome drug discovery

It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent.

To capitalise on the microbiome’s potential to improve human health, biotech and pharmaceutical companies are devoting greater resources to microbiome-related initiatives, spurring a spike in investments and collaborations.

Incorporating this potentially disruptive technology into the highly-structured process of drug discovery requires new approaches, thinking and tools.

By Dr Alexander C. Maue

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free